BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: A single center analysis. World J Gastroenterol 2013; 19(36): 6077-6083 [PMID: 24106409 DOI: 10.3748/wjg.v19.i36.6077] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Pagano D, Khouzam S, Magro B, Barbara M, Cintorino D, di Francesco F, Li Petri S, Bonsignore P, Calamia S, Deiro G, Cammà C, Canzonieri M, Gruttadauria S. How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation? Front Oncol 2022;12:929607. [DOI: 10.3389/fonc.2022.929607] [Reference Citation Analysis]
2 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Reference Citation Analysis]
4 Magro B, Pinelli D, De Giorgio M, Lucà MG, Ghirardi A, Carrobio A, Baronio G, Del Prete L, Nounamo F, Gianatti A, Colledan M, Fagiuoli S. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria. Cancers (Basel) 2021;13:5976. [PMID: 34885087 DOI: 10.3390/cancers13235976] [Reference Citation Analysis]
5 Cunha GM, Hosseini M, Furlan A, Fowler KJ. Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. AJR Am J Roentgenol 2021;:1-10. [PMID: 34406054 DOI: 10.2214/AJR.21.26436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5162-79. [PMID: 34410432 DOI: 10.1007/s00261-021-03248-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ng AC. Stick to Milan: Infeasibility of the Brazil-Milan Criteria in recommending patients with hepatocellular carcinoma for liver transplantation. Ann Hepatol 2021;25:100537. [PMID: 34547478 DOI: 10.1016/j.aohep.2021.100537] [Reference Citation Analysis]
8 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405 [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
9 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
10 Morgul MH, Felgendreff P, Kienlein A, Gauger U, Semmling K, Hau HM, Tautenhahn HM, Bartels M. Milan criteria in the MELD era-is it justifiable to extend the limits for orthotopic liver transplantation?World J Surg Oncol. 2020;18:158. [PMID: 32635931 DOI: 10.1186/s12957-020-01932-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gui CH, Baey S, D'cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. Eur J Surg Oncol 2020;46:763-71. [PMID: 31937433 DOI: 10.1016/j.ejso.2020.01.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 17.0] [Reference Citation Analysis]
12 Feng J, Zhu R, Feng D, Yu L, Zhao D, Wu J, Yuan C, Chen J, Zhang Y, Zheng X. Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation. Sci Rep 2019;9:15855. [PMID: 31676847 DOI: 10.1038/s41598-019-52427-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Wang LY, Zheng SS. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ Sci B 2018;19:497-504. [PMID: 29971988 DOI: 10.1631/jzus.B1700156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
14 Thorat A, Jeng LB, Yang HR, Yeh CC, Hsu SC, Chen TH, Poon KS. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors. Ann Hepatobiliary Pancreat Surg 2017;21:205-11. [PMID: 29264583 DOI: 10.14701/ahbps.2017.21.4.205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
15 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
16 Feng J, Chen J, Zhu R, Yu L, Zhang Y, Feng D, Kong H, Song C, Xia H, Wu J, Zhao D. Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection. Oncotarget 2017;8:63299-310. [PMID: 28968990 DOI: 10.18632/oncotarget.18799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
17 León Díaz FJ, Pérez Daga JA, Sánchez Pérez B, Fernández Aguilar JL, Montiel Casado C, Aranda Narváez JM, Suárez Muñoz MA, Romacho López L, Santoyo Villalba J, Santoyo Santoyo J. Up-to-7 Criteria for Hepatocellular Carcinoma Liver Transplantation: A Retrospective Analysis of Experiences. Transplant Proc 2016;48:2969-72. [PMID: 27932121 DOI: 10.1016/j.transproceed.2016.08.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Milgrom DP, Maluccio MA, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep 2016;4. [DOI: 10.1007/s40137-016-0143-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7(4): 649-661 [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
20 Suh KS, Lee HW. Liver transplantation for advanced hepatocellular carcinoma: how far can we go? Hepat Oncol 2015;2:19-28. [PMID: 30190984 DOI: 10.2217/hep.14.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
21 Jiang L, Lei JY, Wang WT, Yan LN, Li B, Wen TF, Xu MQ, Yang JY, Wei YG. Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE. J Gastrointest Surg 2014;18:1125-30. [DOI: 10.1007/s11605-014-2508-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]